Document is current
Any future updates will be listed below
-
Authors
Qi, Cancan
Liu, Zhaoli
Kilic, Gizem
Sarlea, Andrei S.
Debisarun, Priya A.
Liu, Xuan
Mekonnen, Yonatan Ayalew
Li, Wenchao
Grasshoff, Martin
Alaswad, Ahmed
Petkoglou, Apostolos
Koeken, Valerie A. C. M.
Moorlag, Simone J. C. F. M.
de Bree, L. Charlotte J.
Mourits, Vera P.
Joosten, Leo A. B.
Li, Yang
Netea, Mihai G.
Xu, Cheng-Jian https://orcid.org/0000-0003-1586-4672
-
Funding
Funding for this research was provided by:
European Research Council (948207, 833247)
Helmholtz Initiative and Networking Fund (1800167)
Deutsche Forschungsgemeinschaft (497673685)
National Natural Science Foundation of China (82302610)
Medizinische Hochschule Hannover (MHH)
- License Information
-
More Information
Article History
Received: 2 November 2023
Accepted: 8 May 2025
First Online: 9 July 2025
Declarations
:
: The 300BCG study was approved by the Arnhem-Nijmegen Medical Ethical Committee (NL58553.091.16). All participants have given written informed consent.
: MGN is the scientific founder of TTxD, Lemba, Salvina, and Biotrip. LABJ is the scientific founder of TTxD, Lemba, and Salvina. None of these start-ups have objectives that intersect with this study. The other authors declare that they have no competing interests.
